|
|
|
|
|
|
|
Economic Times Biz Listings |
|
Vijay Kedia turns poet to get over lockdown blues As investors grappled with the fear of the unknown on Dalal Street amid the 21-day nationwide lockdown due to the coronavirus pandemic, market veteran Vijay Kedia remained calm and carefree as ever. He even penned poems, satirising the market mood amid a merciless selloff. And, as always, he circulated his trademark motivational lines on group platforms, trying to keep friends and followers upbeat as the nationwide shutdown and stocks selloff cast a pall of gloom all around. Listen-in. (Text: ETMarkets.com) | 5 pharma stocks that can potentially safeguard your portfolio The novel coronavirus pandemic has caused severe supply-side disruptions in various sectors and earnings will be cut by 10-15%. Pharma as a sector has emerged as a strong contender to drive the next leg of the rally, whenever it comes. In anticipation, pharma stocks have seen a huge run-up in the last 10 days. This is not just true for India, but globally too pharma companies has performed well. While in the short term, most companies will bounce back from the last 5 year of underperformance, this time around, the leader will be different. Hence, you need to choose your stocks carefully. The following are the strong tactical buys with strong catalysts. (Source: Edelweiss Securities)
| |
|
|
|
|
|
Real Estate News |
|
|
|
|
|
|
|
Views and Recommendations |
|
|
More Newsletters |
|
Special stories that round up the major developments of the day | | |
|
|
Round up of stock, currency, bond, money and real estate market | | |
|
|
Latest in the world of fashion, technology, food and celebrity | | |
|
|
Weekly news on personal finance, stocks, property, gold, tax planning and more | | |
|
View All |
|
|
|
ET Investment Opportunities is now part of your favourite ET Wealth mailer. Property, Stocks, IPOs, NFOs and Mutual Funds – get the latest investment options in your mail box every week with ET Investment Opportunities. |
To unsubscribe or edit your subscriptions please click here |
No comments:
Post a Comment